News
Lantern Pharma (LTRN) announced that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback